Virtu Financial LLC Makes New $601,000 Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Virtu Financial LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,051 shares of the medical research company's stock, valued at approximately $601,000.

Other large investors have also recently modified their holdings of the company. Toronto Dominion Bank increased its holdings in shares of Charles River Laboratories International by 1.6% in the third quarter. Toronto Dominion Bank now owns 25,617 shares of the medical research company's stock worth $5,046,000 after purchasing an additional 397 shares during the period. Neo Ivy Capital Management purchased a new position in Charles River Laboratories International during the third quarter worth about $966,000. Gould Capital LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth about $1,225,000. M&T Bank Corp raised its holdings in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after acquiring an additional 66 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. boosted its position in shares of Charles River Laboratories International by 13.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company's stock valued at $3,071,000 after acquiring an additional 1,882 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 2.0 %

CRL traded down $3.81 on Friday, hitting $190.46. The company had a trading volume of 547,747 shares, compared to its average volume of 616,658. The stock has a market capitalization of $9.74 billion, a price-to-earnings ratio of 23.84, a P/E/G ratio of 5.00 and a beta of 1.38. The stock has a fifty day moving average price of $194.35 and a 200-day moving average price of $203.02. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.72 EPS. Analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CRL. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a "sell" rating and a $151.00 price target on the stock. CLSA cut shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a report on Monday, November 11th. UBS Group raised their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Finally, Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Charles River Laboratories International currently has an average rating of "Hold" and an average price target of $214.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).